Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy-Reference-Cited by-同舟云学术

Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy

Published:2014-02-27 Issue:3 Volume:10 Page:237-245
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Lee Se-Hoon¹,Bang Yung-Jue¹,Mainwaring Paul²,Ng Christina³,Chang John W-C⁴,Kwong Philip⁵,Li Rubi K⁶,Sriuranpong Virote⁷,Toh Chee-Keong⁸,Yuan Jinyu⁹,Pitman Lowenthal Susan⁹,Chung Hyun C¹⁰

Affiliation:

1. Department of Internal Medicine; Seoul National University Hospital and Cancer Research Institute; Seoul National University College of Medicine; Seoul South Korea

2. Medical Oncology; Mater Adult Hospital; South Brisbane Queensland Australia

3. Medical Oncology, Department of Medicine; University Malaya Medical Centre; Kuala Lumpur Malaysia

4. Division of Hematology-Oncology, Department of Internal Medicine; Chang Gung Memorial Hospital; Chang Gung University College of Medicine; Taoyuan Taiwan

5. Department of Clinical Oncology; Queen Mary Hospital; Hong Kong China

6. Cancer Institute; St Luke's Medical Center; Quezon City Philippines

7. Medical Oncology Unit, Department of Medicine, Faculty of Medicine; Chulalongkorn University; Bangkok Thailand

8. Department of Medical Oncology; National Cancer Centre; Singapore

9. Pfizer Oncology; New York New York USA

10. Yonsei Cancer Center; Yonsei University College of Medicine; Yonsei University Health System; Seoul South Korea

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12163/fullpdf

Reference23 articles.

1. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer;Abrams;Mol Cancer Ther,2003

2. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin Cancer Res,2003

3. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo;O'Farrell;Blood,2003

4. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

5. Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2009

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib;Frontiers in Pharmacology;2024-07-24

2. Comparative Evaluation of Safety and Efficacy of Alternate Schedule (AS) of Sunitinib in Asian and Non-Asian Patient Population for the Treatment of Metastatic Renal Cell Cancer (mRCC): A Meta-Analysis;Kidney Cancer;2022-03-15

3. Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial;Cancer Medicine;2021-08-18

4. Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma;Medicine;2021-08-06

5. Evaluating predictors of renal injury with sorafenib in hepatocellular carcinoma: A multi-ethnic cohort study;Journal of Onco-Nephrology;2021-04-19